Using inhibitors against kinases mediating BCR signalling, remarkable effects on the anatomical localisation of the CLL cells have been observed in clinical trials, possibly by altering chemokine- and integrin-mediated signal transduction. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.